Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005035 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Study locations
NCT00005035: Completed Phase 2 study of Head and Neck Cancer, sponsored by Ohio State University Comprehensive Cancer Center.
NCT00005035 is a Phase 2 study of Head and Neck Cancer that has completed, run by Ohio State University Comprehensive Cancer Center. The trial reports 11 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005035, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have advanced head and neck cancer.
Conditions Studied
Interventions
- DRUG oxaliplatin
Study Locations (11)
Illinois
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- Decatur Memorial Hospital Cancer Care Institute - Decatur
- Evanston Northwestern Health Care - Evanston
- Lutheran General Cancer Care Center - Park Ridge
- Oncology/Hematology Associates of Central Illinois, P.C. - Peoria
- Central Illinois Hematology Oncology Center - Springfield
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
- Saint Joseph's Regional Medical Center - South Bend
Ohio
- Arthur G. James Cancer Hospital - Ohio State University - Columbus
South Carolina
- Cancer Centers of the Carolinas - Greenville
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
What the finished NCT00005035 record still lists
NCT00005035 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which oxaliplatin is the first listed.
NCT00005035 lists 11 locations in 4 states (Illinois, Indiana, Ohio).
Frequently Asked Questions
What is clinical trial NCT00005035 about?
NCT00005035 is a clinical study titled "Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have advanced head and neck cancer.
What is the current status of trial NCT00005035?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2004-03.
What conditions does trial NCT00005035 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT00005035?
The interventions under investigation include: oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00005035?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005035 being conducted?
This trial has 11 study locations across Illinois, Indiana, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia